Investigation of the efficacy of doxorubicin combined with increased expression of caspase 9 on SH-SY5Y neuroblastoma cell line

Beheshti Shoushtari, Seyed-Hossein; Ataei, Farangis; Hosseinkhani, Saman

Investigation of the efficacy of doxorubicin combined with increased expression of caspase 9 on SH-SY5Y neuroblastoma cell line

Document Type : Original Research

Authors

Seyed-Hossein Beheshti Shoushtari ¹

Farangis Ataei ²

Saman Hosseinkhani ²

¹ Tarbiat Modares university

² Tarbiat Modares University

Abstract

SH-SY5Y is a neuroblastoma cell line which used as a cancer and neurodegenerative disorders model and its neuro-experimental studies. The different diseases cause by a defect in apoptosis pathway. Disruption of apoptotic proteins has an effect on the treatment process and response to drugs. In nerve cells, due to the high expression of apoptosis inhibitory proteins, the efficacy of drugs is low. Combination therapy is one of the developing treatment methods. The aim of this research is to evaluate the effectiveness of doxorubicin drug on apoptosis in SH-SY5Y cells under the conditions of high expression of caspase9. Caspase9 is a key enzyme in intrinsic apoptosis. First, cell viability was obtained through MTT assay under the different drug concentrations. Then, caspase9 gene was transfected in cells and affected by the concentration lower than IC50 of drug, and cell energy level and cell death were checked by different methods. ATP assay showed that the expression of caspase9 with drug lead to ATP decreases. Caspase3/7 activity indicated an increase in cell death by drug and caspase. Propidium staining to hoechst showed that the expression of caspase9 in combination with doxorubicin induce more death. To ensure the expression levels of protein that induces cell death, the amount of caspase3 protein was checked by western blotting, which showed a significant increase in combination of caspase9 and drug. Our findings showed that the induction of caspase9 expression intensifies the effect of drug and the combined treatment may be effective on the responsiveness of neuronal diseases.

Keywords

SH-SY5Y

Caspase 9

Cell death

drug

cell energy

Subjects

Pharmaceutical Biotechnology

[1] S. Elmore, “Apoptosis: a review of programmed cell death,” Toxicol. Pathol., vol. 35, no. 4, pp. 495–516, 2007.
[2] A. Lawen, “Apoptosis—an introduction,” Bioessays, vol. 25, no. 9, pp. 888–896, 2003.
[3] N. E. Crook, R. J. Clem, and L. K. Miller, “An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif,” J. Virol., vol. 67, no. 4, pp. 2168–2174, 1993.
[4] B. M. Reza et al., “Combination therapy in combating cancer,” Oncotarget, vol. 8, no. 3, pp. 3822–3843, 2017.
[5] M. Asadi et al., “Caspase‐3: structure, function, and biotechnological aspects,” Biotechnol. Appl. Biochem., vol. 69, no. 4, pp. 1633–1645, 2022.
[6] W. C. Earnshaw, L. M. Martins, and S. H. Kaufmann, “Mammalian caspases: structure, activation, substrates, and functions during apoptosis,” Annu. Rev. Biochem., vol. 68, no. 1, pp. 383–424, 1999.
[7] G. M. Cohen, “Caspases: the executioners of apoptosis,” Biochem. J., vol. 326, no. 1, pp. 1–16, 1997.
[8] N. Van Opdenbosch and M. Lamkanfi, “Caspases in cell death, inflammation, and disease,” Immunity, vol. 50, no. 6, pp. 1352–1364, 2019.
[9] M. M. Shipley, C. A. Mangold, and M. L. Szpara, “Differentiation of the SH-SY5Y human neuroblastoma cell line,” JoVE (Journal Vis. Exp., no. 108, p. e53193, 2016.
[10] K. Mehdizadeh, F. Ataei, and S. Hosseinkhani, “Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel,” Med. Oncol., vol. 38, no. 6, p. 64, 2021.
[11] M. Torkzadeh-Mahani, F. Ataei, M. Nikkhah, and S. Hosseinkhani, “Design and development of a whole-cell luminescent biosensor for detection of early-stage of apoptosis,” Biosens. Bioelectron., vol. 38, no. 1, pp. 362–368, 2012.
[12] K. Mehdizadeh, F. Ataei, and S. Hosseinkhani, “Effects of doxorubicin and docetaxel on susceptibility to apoptosis in high expression level of survivin in HEK and HEK-S cell lines as in vitro models,” Biochem. Biophys. Res. Commun., vol. 532, no. 1, pp. 139–144, 2020.
[13] M. Tiwari et al., “Apoptosis in mammalian oocytes: a review,” Apoptosis, vol. 20, pp. 1019–1025, 2015.
[14] S. Mukhopadhyay, P. K. Panda, N. Sinha, D. N. Das, and S. K. Bhutia, “Autophagy and apoptosis: where do they meet?,” Apoptosis, vol. 19, pp. 555–566, 2014.
[15] T.-J. Fan, L.-H. Han, R.-S. Cong, and J. Liang, “Caspase family proteases and apoptosis,” Acta Biochim. Biophys. Sin. (Shanghai)., vol. 37, no. 11, pp. 719–727, 2005.
[16] C. Riccardi and I. Nicoletti, “Analysis of apoptosis by propidium iodide staining and flow cytometry,” Nat. Protoc., vol. 1, no. 3, pp. 1458–1461, 2006.
[17] S. A. Latt, G. Stetten, L. A. Juergens, H. F. Willard, and C. D. Scher, “Recent developments in the detection of deoxyribonucleic acid synthesis by 33258 Hoechst fluorescence.,” J. Histochem. Cytochem., vol. 23, no. 7, pp. 493–505, 1975.
[18] W. Yaoxian, Y. Hui, Z. Yunyan, L. Yanqin, G. Xin, and W. Xiaoke, “Emodin induces apoptosis of human cervical cancer hela cells via intrinsic mitochondrial and extrinsic death receptor pathway,” Cancer Cell Int., vol. 13, no. 1, pp. 1–8, 2013.
[19] S. Kumar, A. S. Pathania, A. K. Saxena, R. A. Vishwakarma, A. Ali, and S. Bhushan, “The anticancer potential of flavonoids isolated from the stem bark of Erythrina suberosa through induction of apoptosis and inhibition of STAT signaling pathway in human leukemia HL-60 cells,” Chem. Biol. Interact., vol. 205, no. 2, pp. 128–137, 2013.
[20] A. M. Alabsi et al., “Induction of caspase-9, biochemical assessment and morphological changes caused by apoptosis in cancer cells treated with goniothalamin extracted from Goniothalamus macrophyllus,” Asian Pacific J. Cancer Prev., vol. 14, no. 11, pp. 6273–6280, 2013.
[21] J. Pham, B. Brownlow, and T. Elbayoumi, “Mitochondria-specific pro-apoptotic activity of genistein lipidic nanocarriers,” Mol. Pharm., vol. 10, no. 10, pp. 3789–3800, 2013.
[22] B. Kim, S. K. Srivastava, and S.-H. Kim, “Caspase-9 as a therapeutic target for treating cancer,” Expert Opin. Ther. Targets, vol. 19, no. 1, pp. 113–127, 2015.
[23] U. Fischer and K. Schulze-Osthoff, “Apoptosis-based therapies and drug targets,” Cell Death Differ., vol. 12, no. 1, pp. 942–961, 2005.
[24] X. Zhou, A. Di Stasi, and M. K. Brenner, “iCaspase 9 suicide gene system,” Gene Ther. Solid Cancers Methods Protoc., pp. 87–105, 2015.
[25] J. D. Iuliucci et al., “Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers,” J. Clin. Pharmacol., vol. 41, no. 8, pp. 870–879, 2001.
[26] Q. TONG et al., “Natural jasmonates of different structures suppress the growth of human neuroblastoma cell line SH‐SY5Y and its mechanisms 1,” Acta Pharmacol. Sin., vol. 29, no. 7, pp. 861–869, 2008.
[27] A. J. Primeau, A. Rendon, D. Hedley, L. Lilge, and I. F. Tannock, “The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors,” Clin. Cancer Res., vol. 11, no. 24, pp. 8782–8788, 2005.
[28] S. Sharifi, J. Barar, M. S. Hejazi, and N. Samadi, “Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells,” Adv. Pharm. Bull., vol. 5, no. 3, p. 351, 2015.